GMP– tag –
-
iPSC Product Quality Defined in Differentiation: Core of Process Development for GMP Manufacturing
Made Scientific USA Overview Made Scientific highlights that the quality of iPSC-derived products is established during the differentiation development phase, making subsequent improvements challenging. Current differentiation protocols ... -
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows
BioBucks United States Overview Merck KGaA has agreed to acquire life science tools provider Bio-Techne for $11.3 billion, a strategic move to significantly enhance its life science division. This acquisition deepens Merck KGaA's exposur... -
Cell and Gene Therapy GMP Services Market Forecast to Reach $5.88 Billion by 2030, Growing at 18.9% CAGR
The Business Research Company Global Overview The Business Research Company released a report forecasting the GMP services market for cell and gene therapy to reach $2.95 billion in 2026 and expand to $5.88 billion by 2030, exhibiting an... -
Northway Biotech Inaugurates €61 Million Cell Therapy CDMO Facility in Vilnius, First in the Baltics
PR Newswire Lithuania Overview Northway Biotech has invested €61 million to establish the Baltic states' first large-scale Contract Development and Manufacturing Organization (CDMO) facility for cell therapy and personalized medicine in ... -
REPROCELL Publishes Article on Scaling iPSC Manufacturing: Addressing Challenges from Cell Line Development to Clinical Production
REPROCELL Japan Overview REPROCELL has published an article titled "Scaling iPSC Manufacturing: From Cell Line Development to Clinical Production," focusing on the crucial aspects of industrializing induced pluripotent stem cell (iPSC) t... -
Cellistic Expands iPSC Therapy Manufacturing with New GMP Platforms for Immuno-Oncology and Regenerative Medicine
Cellistic Press Release (via PharmaTimes) Belgium Overview Cellistic has introduced three new GMP manufacturing platforms—Echo-T, Echo-Cardio, and Echo-Endothelial—significantly expanding its capabilities for iPSC-derived cell therapies.... -
AI-Guided 3D Bioreactors Revolutionize iPSC Manufacturing: Scaling Up and Cutting Costs for Accelerated Commercialization
Wiley Analytical Science USA Overview AI-guided 3D bioreactor technology is revolutionizing iPSC manufacturing, enabling reliable, efficient, and scalable production of pluripotent stem cells (PSCs). This innovative platform facilitates ... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
6th iPSC Drug Development Summit Focuses on Manufacturability, Regulatory Alignment, and Scalable Development Models
RegMedNet UK Overview The 6th iPSC Drug Development Summit is being held to actively discuss the clinical and commercial feasibility of iPSC therapies. The summit will focus on manufacturability, alignment with regulatory authorities, an... -
Commercial-Scale iPSC Cell Therapy Production Gains Traction with US Clinical Trial Progress and Master Cell Bank Establishment
The Medicine Maker UK Overview Manufacturing challenges for commercial-scale iPSC cell therapies are being overcome, with multiple iPSC clinical trials progressing in the U.S. for indications like Type 1 Diabetes, Parkinson's disease, an...
